CG
CGEN.US Compugen
- Market cap
- USD 199M
- P/E
- 5.4x
- P/B
- 2.40x
- ROE
- -32.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CGEN.US undervalued?
Graham numberCGEN.US trades 24.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Compugen fundamental analysis
No fundamental analysis for Compugen yet.
Compugen stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy an…
Full company profileCompugen financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Compugen annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 712K | 0.00 | 17.8M | 0.00 | 2.00M | 6.00M | 7.50M | 33.5M | 27.9M | 72.8M | 11.5M |
| Gross Profit | 489K | -1.59M | 16.8M | -989K | 1.94M | 5.32M | 6.53M | 31.5M | 19.9M | 63.5M | 2.24M |
| Operating Income | -32.6M | -37.4M | -23.2M | -28.9M | -31.5M | -35.1M | -35.4M | -13.0M | -14.9M | 31.3M | -32.9M |
| EBITDA | -31.1M | -35.8M | -21.8M | -27.9M | -30.8M | -34.6M | -34.9M | -9.28M | -9.19M | 35.9M | -28.7M |
| Net Income | -31.5M | -37.1M | -22.6M | -27.3M | -27.3M | -32.9M | -33.7M | -18.8M | -14.2M | 35.3M | -27.3M |
| EPS | -0.62 | -0.72 | -0.41 | -0.43 | -0.34 | -0.39 | -0.39 | -0.21 | -0.16 | 0.38 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 71.1M | 38.7M | 53.2M | 53.8M | 138M | 132M | 94.2M | 121M | 115M | 157M | 130M |
| Total Liabilities | 7.62M | 9.45M | 15.9M | 15.4M | 18.5M | 25.5M | 16.5M | 55.8M | 60.1M | 53.8M | 46.2M |
| Shareholders' Equity | 63.5M | 29.3M | 37.2M | 38.3M | 120M | 107M | 77.7M | 65.6M | 54.9M | 103M | 83.4M |
| Cash & Short-term Investments | 61.5M | 30.4M | 45.7M | 43.9M | 124M | 117M | 83.3M | 50.7M | 103M | 146M | 118M |
| Total Debt | - | - | - | 3.58M | 3.17M | 2.75M | 1.93M | 1.35M | 2.91M | 2.96M | 2.79M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.8M | -30.7M | -13.3M | -27.9M | -28.3M | -22.7M | -34.1M | -35.9M | 49.6M | 31.6M | - |
| Capital Expenditure | 2.60M | 385K | 158K | 155K | 166K | 292K | 487K | 172K | 118K | 306K | 0.00 |
| Free Cash Flow | -22.4M | -31.0M | -13.4M | -28.0M | -28.5M | -23.0M | -34.6M | -36.1M | 49.5M | 31.3M | - |
| Ratios | |||||||||||
| ROE | -49.6% | -126.5% | -60.7% | -71.3% | -22.8% | -30.8% | -43.4% | -28.6% | -25.9% | 34.4% | -32.7% |
| ROA | -44.3% | -95.7% | -42.5% | -50.8% | -19.7% | -24.9% | -35.8% | -15.5% | -12.4% | 22.6% | -21.1% |
| Net Profit Margin | -4,425.0% | - | -127.0% | - | -1,363.0% | -547.9% | -449.3% | -56.1% | -51.1% | 48.6% | -238.1% |
| Debt to Equity | - | - | - | 0.09x | 0.03x | 0.03x | 0.02x | 0.02x | 0.05x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Compugen dividends
Compugen has not paid dividends in the last 9 fiscal years.
Who owns Compugen
- Insiders 0.39%
- Institutions 15.07%
- Public & others 84.54%
- Shares outstanding 94.7M
- Free float 94.6M
Top funds holding CGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nomura Healthcare Fund Class I | 1.02M | 1.08% | 0.00% | Sep 2026 |
| ARK Israel Innovative Technology ETF | 975K | 1.03% | 0.00% | Oct 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 357K | 0.38% | 0.00% | Oct 2026 |
| Taylor Frigon Core Growth | 243K | 0.26% | 0.00% | Aug 2026 |
| Avantis International Small Cap Val ETF | 87.4K | 0.09% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 76.6K | 0.08% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 46.0K | 0.05% | +1.92% | Oct 2026 |
| Avantis Global Small Cap Val ETF USD Acc | 34.9K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 31.4K | 0.03% | -44.61% | Aug 2026 |
| DFA International Core Equity 2 I | 31.4K | 0.03% | -14.27% | Sep 2026 |
| Avantis® International Equity Instl | 17.3K | 0.02% | 0.00% | Sep 2026 |
| Avantis Responsible International Eq ETF | 11.8K | 0.01% | 0.00% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 9.92K | 0.01% | -0.30% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 8.70K | 0.01% | -0.40% | Sep 2026 |
| Dimensional VA International Small Port | 8.38K | 0.01% | 0.00% | Sep 2026 |
| Avantis CIBC Global Small Cap Value ETF | 5.40K | 0.01% | 0.00% | Aug 2026 |
| DFA International Core Equity Class F | 5.29K | 0.01% | 0.00% | Aug 2026 |
| Dimensional Global Trgtd Value USD Acc | 5.05K | 0.01% | -0.41% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 4.49K | 0.00% | 0.00% | Sep 2026 |
| Harbor AlphaEdge Small Cap Growth ETF | 2.22K | 0.00% | 0.00% | Oct 2026 |
Compugen company profile
- Company name
- Compugen
- Ticker
- CGEN.US
- ISIN
- IL0010852080
- Exchange
- USA Stocks
- Listed since
- Aug 11, 2000
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 75
- Fiscal year end
- December
- Address
- Azrieli Center, Holon, Israel, 5885849
- Phone
- 972 3 765 8585
- Website
- cgen.com
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen management
10- Dr. Anat Cohen-Dayag Ph.D.Executive Chair · born 1967
- Dr. Eran Ophir Ph.D.CEO, President & Director · born 1978
- Dr. Pierre Ferre Ph.D.Chief Operating Officer · born 1977
- Dr. Zurit Levine Ph.D.Senior Vice President of Business Development · born 1968
- Ms. Michelle Mahler M.D.Chief Medical Officer
- Mr. David Silberman CPAChief Financial Officer · born 1984
- Ms. Lindsey TrickettHead of Investor Relations and Corporate Communications
- Mr. Eran Ben DorGeneral Counsel & Corporate Secretary
- Ms. Dorit AmitayVice President of Human Resources · born 1968
- Rivka SchwartzVice President Research and Discovery